138661-02-6

138661-02-6 structure

Name: Pentetreotide
Chemical Name: Pentetreotide
CAS Number: 138661-02-6
Molecular Formula: C₆₃H₈₇N₁₃O₁₉S₂
Molecular Weight: 1380.54000
Catalog: Research Areas Cancer
Create Date: 2018-07-09 15:24:20
Modify Date: 2024-01-04 18:18:52
Pentetreotide is a diethylenetriaminopentaacetic (DTPA) conjugate of Octreotide. Pentetreotide is an indium-labelled somatostatin analog and can be uesd to nuclear medicine imaging. Somatostatin receptor scintigraphy with Pentetreotide is effective in visualizing neuroendocrine tumors, and its metastasis[1][2].

Name	Pentetreotide
Synonyms	Pentreotide [DTPA-D-Phe1]octreotide N-(2-((2-(Bis(carboxymethyl)amino)ethyl)(carboxymethyl)amino)ethyl)-N-(carboxymethyl)glycyl-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (3-8)-disulfide L-Cysteinamide,N-[2-[[2-bis(carboxymethyl)amino]-ethyl](carboxymethyl)amino]ethyl]-N-(carboxymethyl)glycyl-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-,cyclic (3-8)-disulfide N-[2-[[2-[Bis(carboxymethyl)amino]ethyl](carboxymethyl)amino]ethyl]-N-(carboxymethyl)-Gly-D-Phe-L-Cys(1)-L-Phe-D-Trp-L-Lys-L-Thr-L-Cys(1)-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-NH2 Unii-G083B71p98 DTPA-octreotide DTPA-SMS CA index name: L-Cysteinamide,N-[2-[[2-bis(carboxymethyl)amino]-ethyl](carboxymethyl)amino]ethyl]-N-(carboxymethyl)glycyl

Description	Pentetreotide is a diethylenetriaminopentaacetic (DTPA) conjugate of Octreotide. Pentetreotide is an indium-labelled somatostatin analog and can be uesd to nuclear medicine imaging. Somatostatin receptor scintigraphy with Pentetreotide is effective in visualizing neuroendocrine tumors, and its metastasis[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
In Vitro	Neuroendocrine tumors have an increased number of somatostatin receptors, as compared to normal tissues. At present time, there are five known subtypes. Somatostatin receptor scintigraphy with 111In-Pentetreotide binds to two of these subtypes and is effective in visualizing neuroendocrine tumors, and its metastasis with an overall diagnostic sensitivity of 70% to 90%. It is considerably more sensitive than conventional anatomic imaging. Its usage in neuroendocrine tumors not only includes assessment of disease extent, but also in identified primary lesion, assesses treatment response, and selection for radionuclide therapy[1].
References	[1]. Al-Suqri B. 111 In-pentetreotide SPECT CT Value in Follow-up of Patients with Neuro-Endocrine Tumors. Oman Med J. 2014 Sep;29(5):362-4. [2]. Masuda R, et al. Concise site-specific synthesis of DTPA-peptide conjugates: application to imaging probes for the chemokine receptor CXCR4. Bioorg Med Chem. 2011 May 15;19(10):3216-20.